<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005666</url>
  </required_header>
  <id_info>
    <org_study_id>CRL/CT/09/11-12</org_study_id>
    <nct_id>NCT02005666</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel</brief_title>
  <official_title>A Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel (of Cadila Healthcare Limited, India) Versus DUAC® Gel (of Stiefel Laboratories, USA) Versus Placebo (Vehicle Gel) in the Ratio of 2:2:1 Respectively, in Patients With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo&#xD;
      Controlled, Three Arm Clinical Study.&#xD;
&#xD;
      The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate&#xD;
      1.2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC® Gel of&#xD;
      Stiefel Laboratories)in the ratio of 2:2:1 of Test drug, Reference drug and Placebo&#xD;
      respectively.&#xD;
&#xD;
      Total study duration will be for a period of 78 days which includes treatment duration of 77&#xD;
      days.&#xD;
&#xD;
      850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria&#xD;
      mentioned in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 28, 2016</completion_date>
  <primary_completion_date type="Actual">September 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions.</measure>
    <time_frame>week 11</time_frame>
    <description>Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions in PP populations. The primary endpoint of the study is mean percent change from baseline to week 11 (study Day 77) in the inflammatory (papules and pustules) lesion count.&#xD;
Papule was Inflammatory lesion; small (&lt; 5mm in diameter), solid palpable lesion, usually with inflamed elevation of the skin that does not contain pus. Pustule was Inflammatory lesion; small (&lt; 5mm in diameter), inflamed skin swelling that is filled with pus. The test product was judged therapeutically equivalent to the reference product in the reduction of inflammatory lesions if the 90% confidence interval was contained within the interval (0.80, 1.25)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline to Week 11 in the Non-inflammatory Lesion Count</measure>
    <time_frame>week 11</time_frame>
    <description>Mean percent change from baseline to week 11 in the non-inflammatory lesion count. The mean percent change from baseline to week 11 in the non-inflammatory (open and closed comedones) lesion count in per protocol population . The analysis was same as the analysis performed for the mean percent reduction from baseline to Day 77 in the number of inflammatory lesion count.&#xD;
Closed Comedone was Non-inflammatory lesion; whitehead, skin-colored or slightly inflamed &quot;bump&quot; in the skin. Open Comedone was Non-inflammatory lesion; blackhead, surface of the plugged sebaceous follicle has a blackish appearance. The test product was judged therapeutically equivalent to the reference product in the reduction of Non inflammatory lesions if the 90% confidence interval was contained within the interval (0.80, 1.25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With a Clinical Response of &quot;Success&quot; at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Success was defined as an Investigator Global Assessment (IGA) score that is at least 2 grades less than the baseline assessment.&#xD;
Percentage of subjects with at least 2 grades improvement in IGA scoring from baseline to week 11 for test, reference and placebo in Per protocol population.&#xD;
IGA is evaluated in the range of 0 to 4. Grade 0=Clear skin with no inflammatory or non-inflammatory lesions;Grade 1=Almost clear;rare non-inflammatory lesions with no more than one small inflammatory lesion; Grade 2 = Mild severity; greater than grade 1;some non-inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions);Grade 3 = Moderate severity; greater than Grade 2; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion;Grade 4= Severe; greater than Grade 3;up to many non-inflammatory lesions and may have some inflammatory lesions,but no more than a few nodular lesions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">850</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Test-Cadila healthcare limited</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel</intervention_name>
    <description>Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
    <arm_group_label>Test-Cadila healthcare limited</arm_group_label>
    <other_name>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of CHL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DUAC® Gel</intervention_name>
    <description>Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>DUAC® Gel (of Stiefel Laboratories</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (Vehicle Gel)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis&#xD;
             of Acne vulgaris&#xD;
&#xD;
          2. On the face, ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20&#xD;
             inflammatory lesions (i.e., papules and pustules) AND ≤ 2 nodulocystic lesions (i.e.,&#xD;
             nodules and cysts).&#xD;
&#xD;
          3. Investigator's Global Assessment (IGA) of acne severity grade 2, 3 OR 4&#xD;
&#xD;
          4. Willing to refrain from use of all other topical acne medications or antibiotics&#xD;
             during the 11 week treatment period.&#xD;
&#xD;
          5. If female of childbearing potential, willing to use an acceptable form of birth&#xD;
             control during the study.&#xD;
&#xD;
          6. Have used the same brand of make-up for a minimum period of 2 weeks prior to&#xD;
             randomization, for subjects who use make-up, and agree to not change make-up brands or&#xD;
             types during the study.&#xD;
&#xD;
          7. Willing to provide written informed consent or assent (HIPAA consent/authorization, as&#xD;
             applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any skin condition that would interfere with the diagnosis or assessment&#xD;
             of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell&#xD;
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid&#xD;
             folliculitis, or bacterial folliculitis).&#xD;
&#xD;
          2. Patients who have acne conglobata, acne fulminans and secondary acne (e.g.: chloracne&#xD;
             and drug induced acne).&#xD;
&#xD;
          3. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere&#xD;
             with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.&#xD;
&#xD;
          4. History of hypersensitivity or allergy to benzoyl peroxide or clindamycin and/or any&#xD;
             of the study medication ingredients.&#xD;
&#xD;
          5. Patients who have a severe or intense irritation on the Face.&#xD;
&#xD;
          6. Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g.&#xD;
             Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day&#xD;
             (multivitamins are allowed).&#xD;
&#xD;
          7. Use for less than 3 months prior to baseline (Randomization) of estrogens or oral&#xD;
             contraceptives; use of such therapy is allowed if it will remain constant throughout&#xD;
             the study.&#xD;
&#xD;
          8. Use on the face within 1 month prior to baseline (Randomization) or during the study&#xD;
             of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy,&#xD;
             4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.&#xD;
&#xD;
          9. Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2)&#xD;
             systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris&#xD;
             (other than oral retinoids, which require a 6-month washout), or 5) systemic&#xD;
             anti-inflammatory agents.&#xD;
&#xD;
         10. Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2)&#xD;
             topical retinoids, 3) topical acne treatments including over-the-counter preparations,&#xD;
             4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.&#xD;
&#xD;
         11. Patients who have had general anesthesia for any reason and patients who have received&#xD;
             neuromuscular blocking agents within 14 days prior to study entry (Randomization).&#xD;
&#xD;
         12. Concomitant use of facial product containing glycolic or other acids, masks, washes or&#xD;
             soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or&#xD;
             moisturizers containing retinol, salicylic or α- or β-hydroxy acids.&#xD;
&#xD;
         13. Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12),&#xD;
             haloperidol, halogens such as iodide and bromide, lithium, hydantoin and&#xD;
             phenobarbital.&#xD;
&#xD;
         14. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2&#xD;
             weeks or during the study.&#xD;
&#xD;
         15. Concomitant use of tanning booths or sunbathing.&#xD;
&#xD;
         16. A significant medical history of or are currently immunocompromised&#xD;
&#xD;
         17. Have any systemic or dermatologic disease that may affect the evaluation of study&#xD;
             results.&#xD;
&#xD;
         18. Have a history of regional enteritis, ulcerative colitis, pseudomembranous colitis or&#xD;
             antibiotic-associated colitis.&#xD;
&#xD;
         19. Subjects with clinically significant unstable medical disorders, life-threatening&#xD;
             disease, or current malignancies.&#xD;
&#xD;
         20. Subjects who engage in activities that involve excessive or prolonged exposure to&#xD;
             sunlight.&#xD;
&#xD;
         21. Subjects with History of Alcohol abuse or other drugs of abuse within 2 years prior to&#xD;
             Randomization.&#xD;
&#xD;
         22. Female subjects who are breast-feeding or planning to become pregnant.&#xD;
&#xD;
         23. Subjects who have been treated with an investigational drug or investigational device&#xD;
             within a period of 30 days prior to study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Dharmesh Domadia, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Cliantha Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universal BioPharma Research</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Instititue</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yardley Dermatology Associates</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Research</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmania General Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gandhi Hospital,</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500048</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andrapradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHL Medical College and VS Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC-MET Medical College, Sheth LG General Hospital,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjeevani Hospital,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Leprosy and STI, Civil Hospital and BJ Medical College,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, BYL Nair Hospital and TN medical college, Dr ALNair Road, Mumbai Central,</name>
      <address>
        <city>Mumbai</city>
        <state>Gujarat</state>
        <zip>400 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, New Civil Hospital and Government Medical College</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baroda Medical College</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Bhagawan Mahaveer Jain Hospital Millers Road,Vasanthnagar -</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Kempegowda Institute of Medical Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapthagiri Hospital,</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560073</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Skin &amp; STD, JSS Hospital Ramanuja Road, -</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical Collge</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKP Salve Institute of Medical Siences and Lata Mangeshkar Hospital,</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. D Y Patil Hospital and Research Center</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400706</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipoint Hosp</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411007.</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education &amp; Research (PGIMER)</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Hospital and research Center</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Post graduate medical and Research</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganga Ram Hospital,</name>
      <address>
        <city>Delhi</city>
        <zip>110 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aafp.org/afp/2004/0501/p2123.html</url>
    <description>1. Feldman S, Careccia RE, Barham KL, et al. Diagnosis and treatment of acne. Am Fam Physician</description>
  </link>
  <link>
    <url>http://www.bioline.org.br/pdf?dv09082</url>
    <description>2. NilFroushzadeh MA, Siadat AH, Baradaran EH, Moradi S. Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus Tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to</description>
  </link>
  <link>
    <url>http://www.jahonline.org/article/S1054-139X(08)00271-1/abstract</url>
    <description>3. Irby CE, Yentzer BA, Feldman SR. A Review of Adapalene in the Treatment of Acne Vulgaris. Journal of Adolescent Health</description>
  </link>
  <link>
    <url>http://www.eblue.org/article/S0190-9622(82)70109-4/abstract</url>
    <description>6. Barza M, Goldstein JA, Kane A. Systemic absorption of clindamycin hydrochloride after topical application. Journal of the American Academy of Dermatology</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16509</url>
    <description>Cleocin T® Prescribing Information</description>
  </link>
  <link>
    <url>http://www.eblue.org/article/S0190-9622(82)70116-1/abstract</url>
    <description>Guin JD, Lummis WL. Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. Journal of the American Academy of Dermatology</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC172501</url>
    <description>Plaisnce KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother</description>
  </link>
  <link>
    <url>http://www.eblue.org/article/S0190-9622(81)70004-5/abstract</url>
    <description>Nacht S, Yeung D, Beasley JN, Anjo MD, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. Journal of the American Academy of Dermatology</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050741s019lbl.pdf</url>
    <description>DUAC® Gel Prescribing Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292.pdf</url>
    <description>U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: Acne Vulgaris: Developing Drugs for Treatment.</description>
  </link>
  <reference>
    <citation>Eller MG, Smith RB, Phillips JP. Absorption kinetics of topical clindamycin preparations. Biopharm Drug Dispos. 1989 Sep-Oct;10(5):505-12.</citation>
    <PMID>2804254</PMID>
  </reference>
  <reference>
    <citation>Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alió AB. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis. 2009 Oct;84(4):223-9.</citation>
    <PMID>19911678</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>DUAC</keyword>
  <keyword>CADILA</keyword>
  <keyword>CLIANTHA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test-Cadila Healthcare Limited</title>
          <description>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
        <group group_id="P2">
          <title>Reference-DUAC® Gel</title>
          <description>DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="299"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test-Cadila Healthcare Limited</title>
          <description>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
        <group group_id="B2">
          <title>Reference-DUAC® Gel</title>
          <description>DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="338"/>
            <count group_id="B2" value="343"/>
            <count group_id="B3" value="169"/>
            <count group_id="B4" value="850"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 - 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions.</title>
        <description>Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions in PP populations. The primary endpoint of the study is mean percent change from baseline to week 11 (study Day 77) in the inflammatory (papules and pustules) lesion count.&#xD;
Papule was Inflammatory lesion; small (&lt; 5mm in diameter), solid palpable lesion, usually with inflamed elevation of the skin that does not contain pus. Pustule was Inflammatory lesion; small (&lt; 5mm in diameter), inflamed skin swelling that is filled with pus. The test product was judged therapeutically equivalent to the reference product in the reduction of inflammatory lesions if the 90% confidence interval was contained within the interval (0.80, 1.25)</description>
        <time_frame>week 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test-Cadila Healthcare Limited</title>
            <description>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Reference-DUAC® Gel</title>
            <description>DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions.</title>
          <description>Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions in PP populations. The primary endpoint of the study is mean percent change from baseline to week 11 (study Day 77) in the inflammatory (papules and pustules) lesion count.&#xD;
Papule was Inflammatory lesion; small (&lt; 5mm in diameter), solid palpable lesion, usually with inflamed elevation of the skin that does not contain pus. Pustule was Inflammatory lesion; small (&lt; 5mm in diameter), inflamed skin swelling that is filled with pus. The test product was judged therapeutically equivalent to the reference product in the reduction of inflammatory lesions if the 90% confidence interval was contained within the interval (0.80, 1.25)</description>
          <units>percentage of mean change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.6" spread="28.39"/>
                    <measurement group_id="O2" value="-71.3" spread="25.98"/>
                    <measurement group_id="O3" value="-51.9" spread="33.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline to Week 11 in the Non-inflammatory Lesion Count</title>
        <description>Mean percent change from baseline to week 11 in the non-inflammatory lesion count. The mean percent change from baseline to week 11 in the non-inflammatory (open and closed comedones) lesion count in per protocol population . The analysis was same as the analysis performed for the mean percent reduction from baseline to Day 77 in the number of inflammatory lesion count.&#xD;
Closed Comedone was Non-inflammatory lesion; whitehead, skin-colored or slightly inflamed &quot;bump&quot; in the skin. Open Comedone was Non-inflammatory lesion; blackhead, surface of the plugged sebaceous follicle has a blackish appearance. The test product was judged therapeutically equivalent to the reference product in the reduction of Non inflammatory lesions if the 90% confidence interval was contained within the interval (0.80, 1.25)</description>
        <time_frame>week 11</time_frame>
        <population>Total randomized subjects 850,in 2:2:1 ratio(Test:338,Reference:343,Placebo:169).80 subjects withdrawn,770 subjects completed study.Efficacy analysis done in Per Protocol (PP)Population, total 253 subjects were excluded from total randomized subjects.For efficacy analysis,597 subjects considered in PP population (Test:236,Reference:233,Placebo:128)</population>
        <group_list>
          <group group_id="O1">
            <title>Test-Cadila Healthcare Limited</title>
            <description>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Reference-DUAC® Gel</title>
            <description>DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Week 11 in the Non-inflammatory Lesion Count</title>
          <description>Mean percent change from baseline to week 11 in the non-inflammatory lesion count. The mean percent change from baseline to week 11 in the non-inflammatory (open and closed comedones) lesion count in per protocol population . The analysis was same as the analysis performed for the mean percent reduction from baseline to Day 77 in the number of inflammatory lesion count.&#xD;
Closed Comedone was Non-inflammatory lesion; whitehead, skin-colored or slightly inflamed &quot;bump&quot; in the skin. Open Comedone was Non-inflammatory lesion; blackhead, surface of the plugged sebaceous follicle has a blackish appearance. The test product was judged therapeutically equivalent to the reference product in the reduction of Non inflammatory lesions if the 90% confidence interval was contained within the interval (0.80, 1.25)</description>
          <population>Total randomized subjects 850,in 2:2:1 ratio(Test:338,Reference:343,Placebo:169).80 subjects withdrawn,770 subjects completed study.Efficacy analysis done in Per Protocol (PP)Population, total 253 subjects were excluded from total randomized subjects.For efficacy analysis,597 subjects considered in PP population (Test:236,Reference:233,Placebo:128)</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.7" spread="29.50"/>
                    <measurement group_id="O2" value="-61.3" spread="28.46"/>
                    <measurement group_id="O3" value="-42.0" spread="34.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With a Clinical Response of &quot;Success&quot; at Week 11</title>
        <description>Success was defined as an Investigator Global Assessment (IGA) score that is at least 2 grades less than the baseline assessment.&#xD;
Percentage of subjects with at least 2 grades improvement in IGA scoring from baseline to week 11 for test, reference and placebo in Per protocol population.&#xD;
IGA is evaluated in the range of 0 to 4. Grade 0=Clear skin with no inflammatory or non-inflammatory lesions;Grade 1=Almost clear;rare non-inflammatory lesions with no more than one small inflammatory lesion; Grade 2 = Mild severity; greater than grade 1;some non-inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions);Grade 3 = Moderate severity; greater than Grade 2; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion;Grade 4= Severe; greater than Grade 3;up to many non-inflammatory lesions and may have some inflammatory lesions,but no more than a few nodular lesions</description>
        <time_frame>Week 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test-Cadila Healthcare Limited</title>
            <description>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Reference-DUAC® Gel</title>
            <description>DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With a Clinical Response of &quot;Success&quot; at Week 11</title>
          <description>Success was defined as an Investigator Global Assessment (IGA) score that is at least 2 grades less than the baseline assessment.&#xD;
Percentage of subjects with at least 2 grades improvement in IGA scoring from baseline to week 11 for test, reference and placebo in Per protocol population.&#xD;
IGA is evaluated in the range of 0 to 4. Grade 0=Clear skin with no inflammatory or non-inflammatory lesions;Grade 1=Almost clear;rare non-inflammatory lesions with no more than one small inflammatory lesion; Grade 2 = Mild severity; greater than grade 1;some non-inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions);Grade 3 = Moderate severity; greater than Grade 2; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion;Grade 4= Severe; greater than Grade 3;up to many non-inflammatory lesions and may have some inflammatory lesions,but no more than a few nodular lesions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success Rate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure Rate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Day 78</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test-Cadila Healthcare Limited</title>
          <description>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days Other Name: 1.2% Clindamycin Phosphate/ 5%</description>
        </group>
        <group group_id="E2">
          <title>Reference-DUAC® Gel</title>
          <description>DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear deformity acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Scleral cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="338"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="338"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain in Jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="338"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="343"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Mechanical urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mr Anuj K Saini</name_or_title>
      <organization>Cadila Healthcare Limited</organization>
      <phone>02717623666 ext 314</phone>
      <email>Anuj.Saini@zyduscadila.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

